Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles

Abstract Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of αvβ3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against αvβ3 integrins hold promise for anti-cance...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials 2010-03, Vol.31 (8), p.2388-2398
Main Authors: Wagner, Sylvia, Rothweiler, Florian, Anhorn, Marion G, Sauer, Daniel, Riemann, Iris, Weiss, Eike C, Katsen-Globa, Alisa, Michaelis, Martin, Cinatl, Jindrich, Schwartz, Daniel, Kreuter, Jörg, von Briesen, Hagen, Langer, Klaus
Format: Article
Language:English
Subjects:
Advanced Basic Science
Albumin
Chemotherapy
Dentistry
Drug delivery
ECM (extracellular matrix)
Integrin
Nanoparticles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of αvβ3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against αvβ3 integrins hold promise for anti-cancer therapy. DI17E6 is a monoclonal antibody directed against αv integrins that inhibits growth of melanomas in vitro and in vivo and inhibits angiogenesis due to interference with αvβ3 integrins. Here, DI17E6 was covalently coupled to human serum albumin nanoparticles. Resulting nanoparticles specifically targeted αvβ3 integrin positive melanoma cells. Moreover, doxorubicin loaded DI17E6 nanoparticles showed increased cytotoxic activity in αvβ3-positive melanoma cells than the free drug. Therefore, DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into αvβ3-positive cells.
ISSN:0142-9612
1878-5905
DOI:10.1016/j.biomaterials.2009.11.093